26 July 2024 - The positive opinion is based on results from the DELTA phase 3 program, which includes the randomised, vehicle-controlled DELTA 1 and DELTA 2 clinical trials, and the DELTA 3 open-label extension trial.

Leo Pharma today announced that the EMA's CHMP has adopted a positive opinion that recommends the approval of Anzupgo (delgocitinib cream) for the treatment of adult patients with moderate to severe chronic hand eczema, for whom topical corticosteroids are inadequate or inappropriate.

Read Leo Pharma press release